Merck To Acquire Avecia Biologics
Merck & Co and Avecia have entered into a definitive agreement by which Merck will acquire the biologics business of the Avecia group through a Merck affiliate (Merck
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).
Arrayit Diagnostics, a majority-owned subsidiary of Arrayit Corporation, has reported its anticipated timeline for commercialisation of its microarray-based OvaDx pre-symptomatic ovarian cancer blood test. It is currently advancing
Mettler Toledo has presented roller compaction process optimisation using at-line particle characterisation, during the 2009 AAPS Annual Meeting, where the application of in situ particle characterisation was demonstrated
Labopharm has initiated the regulatory approval process for its twice-daily Tramadol-Acetaminophen formulation in Europe under the decentralised procedure (DCP). According to DCP, Labopharm has submitted a marketing authorisation